Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Indium 111In-satumomab pendetide

Known as: B72.3-GYK-DTPA, B72.3-glycyl-tyrosyl N-diethylenetriaminepentacetic acid, Indium In 111 Satumomab Pendetide 
An radioimmunoconjugate of the murine monoclonal antibody, Satumomab (MoAb B72.3), conjugated to the linker-chelator, glycyl-tyrosyl-(N… Expand
National Institutes of Health

Related topics

Related topics

6 relations

Narrower (2)

CYT 103OncoScint

Broader (3)

Monoclonal AntibodiesOligopeptidesPentetic Acid
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Assessment of an 18F-Labeled Phosphoramidate Peptidomimetic as a New Prostate-Specific Membrane Antigen–Targeted Imaging Agent for Prostate Cancer
Prostate-specific membrane antigen (PSMA) is a transmembrane protein commonly found on the surface of late-stage and metastatic… Expand
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Highly Cited
2005
Highly Cited
2005
Correction of photon attenuation and collimator response for a body-contouring SPECT/CT imaging system.
UNLABELLED (111)In-Capromab pendetide imaging is indicated for postprostatectomy patients at risk for residual or recurrent… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2002
Highly Cited
2002
Clinical utility of indium 111‐capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy
Despite the ability of radical prostatectomy to eradicate prostate carcinoma, biochemical evidence of recurrent prostate… Expand
Review
2001
Review
2001
Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer.
PURPOSE Capromab pendetide (ProstaScint) is an indium In 111 ((111)In)-labeled monoclonal antibody to prostate-specific membrane… Expand
Highly Cited
1999
Highly Cited
1999
Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse…
PURPOSE We compare the detection of metastatic disease by helical computerized tomography (CT), positron emission tomography (PET… Expand
Highly Cited
1999
Highly Cited
1999
Platelet kinetic studies in patients with idiopathic thrombocytopenic purpura.
PURPOSE To determine the value in diagnosis and treatment of mean platelet life, platelet production, and major sites of platelet… Expand
Highly Cited
1999
Highly Cited
1999
Comparison of clinical staging algorithms and 111Indium‐capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients
The pretherapy prediction of occult lymph node involvement and the avoidance of otherwise futile and potentially morbid… Expand
Highly Cited
1998
Highly Cited
1998
Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy.
PURPOSE We investigated the ability of In-111-capromab pendetide to separate patients who have failed radical prostatectomy into… Expand
Highly Cited
1998
Highly Cited
1998
Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium‐111 capromab pendetide
Optimum therapy for prostate carcinoma patients requires accurate staging, but computed tomography (CT) and magnetic resonance… Expand
Highly Cited
1992
Highly Cited
1992
Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT.
Immunoscintigraphy performed after intravenous administration of indium-111-labeled CYT-103, an immunoconjugate of monoclonal… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE